← Back to Analyst Consensus 
UPB Buy
Upstream Bio, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 14, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 54% |
| Aug 12, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jun 12, 2026 | JP Morgan | downgrade | Overweight → Neutral | — | 54% |
| Jun 3, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| May 14, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 27, 2026 | Evercore ISI Group | downgrade | Outperform → In-Line | — | 58% |
| Dec 18, 2025 | Mizuho | initiate | — → Outperform | $51 | 52% |
| Dec 2, 2025 | LifeSci Capital | initiate | — → Outperform | $43 | 57% |
| Nov 18, 2025 | Evercore ISI Group | initiate | — → Outperform | $40 | 58% |
| Oct 14, 2025 | Truist Securities | initiate | — → Buy | $47 | 54% |
| Nov 5, 2024 | JP Morgan | initiate | — → Overweight | $38 | 54% |
| Nov 5, 2024 | William Blair | initiate | — → Outperform | $0 | 48% |
| Nov 5, 2024 | TD Cowen | initiate | — → Buy | $0 | 54% |
| Nov 5, 2024 | Piper Sandler | initiate | — → Overweight | $75 | 54% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days